ELOXX PHARMACEUTICALS INC
ELOXNASDAQTrading Snapshot
- Day Range
- $10.03 β $10.94
- 52-Week Range
- $8.20 β $23.40
- Volume (shares)
- 14,981
- Avg Volume (shares)
- β
- Shares Outstanding
- 3.4M
- Next Earnings
- 2027-03-15
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -1.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.38
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +38.9%
ELOXX PHARMACEUTICALS INC
ELOXAbout ELOXX PHARMACEUTICALS INC
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.